Co-incubation of Emb-02 with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Emb-02 was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 1.585 nM.

Emb-02 bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Emb-02 bound to huPD-1-Jurkat cells, and the EC50 was 0.645 nM.

Emb-02 bound to huLAG-3-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Emb-02 bound to huLAG-3-CHO-K cells, and the EC50 was 3.630 nM.

Emb-02 bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Emb-02 bound human PD-1 Protein-His, and the EC50 was 0.011 nM.

Emb-02 bound to LAG-3 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Emb-02 bound human LAG-3 Protein-His, and the EC50 was 0.080 nM.

Anti-LAG-3 & PD-1 Reference Antibody (Emb-02) is 97.15%, determined by SEC-HPLC.

Anti-LAG-3 & PD-1 Reference Antibody (Emb-02) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The detected molecular weight of Anti-LAG-3 & PD-1 Reference Antibody (Emb-02) is 237.40 kDa.